Z.M. and Y.X. authors contributed equally to the work.
Introduction
Detecting prostate cancer lesions, especially clinically significant lesions, is crucial for the effective treatment and accurate prognosis of patients. In recent years, a lesion-based treatment strategy known as targeted focal therapy has emerged [1] . Some studies suggest that focal therapy should eliminate all clinically significant lesions [2] .
Prostate biopsy is the 'gold standard' in the diagnosis of prostate cancer. With regard to the accurate positioning and assessment of prostate cancer, template-guided transperineal biopsy is superior to the transrectal approach [3] [4] [5] ; however, in the detection of small-volume lesions, both methods are associated with a high false-negative rate [6, 7] . Although multiparametric MRI is helpful in the detection of tumour lesions, it is not widely used in firsttime diagnosed prostate cancer because of its expense. It is generally accepted that a full transperineal templatemapping biopsy (biopsy cores taken every 5 mm throughout the prostate) can be used for the preoperative assessment of focal therapy in the absence of MRI results [8, 9] , but whether template-guided saturation biopsy with a general definition (biopsy cores >20) is enough to direct focal therapy needs more evaluation. To perform such an evaluation, it is necessary to assess the tumour detection ability of this technique and to analyse the characteristics of the false-negative lesions.
The aims of the present study were to evaluate the tumour detection ability of template-guided transperineal saturation prostate biopsy by analysing the pathological results of the radical prostatectomy (RP) specimen, and to evaluate the potential impact of undetected lesions by comparing the characteristics of detected and undetected lesions.
Materials and Methods

Study Population
Between June 2013 and June 2016, we analysed the pathological results from 129 template-guided transperineal saturation prostate biopsies and RP specimens. All patients signed the informed consent form provided by the ethics committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. All patients met at least one of the inclusion criteria for prostate biopsy: PSA >4.0 ng/mL; hard nodule on DRE; and suspicion of prostate cancer based on ultrasonography, CT or MRI results. The exclusion criteria included a history of prostate cancer and use of androgen ablation therapy. The patients diagnosed with prostate cancer were further selected for surgery if their PSA level was <50 ng/mL and clinical TNM staging ≤T3aN0M0. Those with a history of prostate cancer treatment (endocrine therapy, radiotherapy or chemotherapy) or incomplete specimen slices were excluded for pathological analysis.
Procedures
Systematic transperineal ultrasonography-guided 11-region biopsy was performed. A biplanar TRUS probe (SONOLINE Adara SLC Ultrasound; Siemens, Erlangen, Germany) and the brachytherapy stepping unit (Computerized Medical System, St Louis, MO, USA) were used. The standard 0.5-cm brachytherapy template was attached to the perineum and biopsy cores were obtained by a transperineal approach through the template grid using the Bard Biopsy gun (C.R. Bard, Covington, GA, USA) and an 18-gauge biopsy needle. Biopsy was implemented within 11 regions on the basis of the anatomical characteristics of the prostate (regions 1-5 represent the right side, regions 6-10 represent the left side and region 11 represents the apical region), which has been described previously [10, 11] . The number of biopsy cores for each patient was >20 and the specific number was determined according to the size of the prostate.
All patients diagnosed with prostate cancer by biopsy underwent laparoscopic RP. The RP specimens were processed into whole-mount slices and scanned into digital forms. The pathological slices were examined by a single pathologist with 14 years of experience. In the enlarged digital slices, we outlined the contours of all lesions, calculated the tumour volume and determined the Gleason score (Fig. 1) . The tumour volume was determined by multiplying the tumour surface area by the thickness of the slice and then multiplying by a correction factor of 1.12 [12] . The prostate was divided by the urethra into anterior and posterior zones or left and right sides. If the proportion of tumour volume anterior to the urethra was >50%, this tumour was called an anterior lesion. Posterior, left-and right-side lesions were classified in the same way. Clinically significant lesions met at least one of the following criteria: tumour volume ≥0.5 mL; Gleason score ≥7; stage ≥T3a; and presence of positive surgical margins [13] . Three-dimensional prostate models were reconstructed using 3D Studio MAX 2015 software (Autodesk, San Rafael, CA, USA). If the lesion in the model overlapped the positive biopsy region, we considered the biopsy able to detect the lesion (Fig. 2 ).
Statistical Analysis
All data were prospectively collected and retrospectively analysed. SPSS 20.0 software (Chicago, IL, USA) was used for statistical analysis. If normally distributed, data were described using mean AE SD values and compared using the independent-sample t-test. If not normally distributed, the data were described using median and interquartile range (IQR) values and compared using the rank-sum test. The chi-squared test was used to compare the rates. A twotailed P value <0.05 was taken to indicate statistical significance. 
Results
General Characteristics of the Patients
The clinical features and pathological results of the patients are shown in Table 1 . The total number of lesions in 129 patients was 353, and 264 (74.8%) were clinically significant. Of all these clinically significant lesions, 107 (40.5%) had tumour volume ≥0.5 mL, 257 (97.3%) had Gleason score ≥7, 22 (8.3%) had T staging ≥T3a, and 27 (10.2%) had a positive surgical margin.
Comparison between the Detected and Undetected Lesions
A total of 203 lesions were detected by biopsy, with a median (IQR) tumour volume of 0.12 (0.03-0.8) mL, while 150 lesions were undetected, with a median (IQR) tumour volume of 0.03 (0.005-0.09) mL. There was a significant difference in tumour volume between the two groups (P < 0.001).
Of the 27 lesions with positive surgical margins, 23 were detected by biopsy. The lesions that were undetected had the following characteristics: volume 0.5 mL, Gleason score 7; volume 0.6 mL, Gleason score 7; volume 0.9 mL, Gleason score 7; and volume 2.1 mL, Gleason score 7.
A comparison of the Gleason scores and spatial locations of the detected and undetected lesions is shown in Table 2 . Of the detected lesions, three that were classified as anterior in the biopsy were classified as posterior lesions in the RP specimens, and four that were classified as posterior in the biopsy were classified as anterior lesions in RP specimens. In addition, six lesions classified as left-side lesions in the biopsy were classified as right-side lesions in the RP specimens, and five lesions classified as right-side lesions in the biopsy were classified as left-side lesions in the RP specimens. Overall, the inconsistencies in lesion position between biopsy and RP specimens for the anterior and posterior zones and the left and right sides were 3.4% (7/203) and 5.4% (11/203), respectively.
Comparison between the Detected and Undetected Clinically Significant Lesions
A comparison between the detected and undetected clinically significant lesions is shown in Table 2 . A total of 64% of the clinically significant lesions (170/264) were detected. Of the (8.5) 129 patients, 13 (10.1%) had undetected clinically significant lesions in the biopsy lying on the same side, but in a different zone from the detected clinically significant lesions, while 23 patients (17.8%) had undetected clinically significant lesions in the biopsy lying on the opposite side from the detected clinically significant lesions. Of all the undetected clinically significant lesions, nine (9.6%) had a tumour volume ≥0.5 mL, 93 (98.9%) had Gleason score ≥7, two (2.1%) had T staging ≥T3a, and four (4.3%) had positive surgical margins.
Discussion
Currently, the avoidance of over-treatment of prostate cancer is a heated topic. Although focal therapy might achieve satisfactory tumour control with less functional changes in short-term follow-up [14] [15] [16] , it is still in the research stage because of lacking long-term clinical data and the existence of controversy regarding the related theory [17, 18] .
In the RP specimen, there are an average of 2-4 lesions in each patient with prostate cancer [19, 20] . There is a lack of consensus regarding the biological behaviour of these different lesions [17, 18] ; therefore, to ensure the validity of treatment, it is particularly important to detect and eliminate effectively the lesions with comparatively high degrees of malignancy.
Prostate biopsy is the gold standard for the diagnosis of prostate cancer. In recent years, as a result of the development of template-guided transperineal biopsy, the positioning and evaluation of prostate cancer has greatly improved [20] . Compared with transrectal biopsy, the biopsy needle in the transperineal approach is parallel to the urethra and can be more effective in sampling the anterior and apical part of the prostate [4, 5] . With the assistance of the template, transperineal biopsy can be performed in a planned way through multiple channels of the skin, to guarantee more balanced sampling and help detect lesions; however, some studies have argued that the approach is still associated with a relatively high false-negative rate. Huo et al. [6] compared the pathological outcomes of transperineal biopsy with those of the RP specimens in a retrospective study in 414 patients. The median number of biopsy cores was 22. The results showed that the overall sensitivity across all biopsy zones was only 48%; therefore, the tumour detection ability of templateguided transperineal saturation prostate biopsy and the characteristics of false-negative lesions it omitted need to be fully evaluated. In the present study, the median number of biopsy cores was 24, and 42% of lesions were undetected (150/353). The false-negative rate was similar to that observed in the study by Huo et al. [6] . On the whole, most of the undetected lesions had small tumour volume (median 0.03 mL) and Gleason score ≤3+4. The distribution of both the detected and the undetected lesions was equal between the anterior and posterior zones, demonstrating the advantage of the transperineal approach in anterior tumour detection. This is supported by previous studies [4, 5] .
The detection of clinically significant lesions is an important issue for prostate biopsy. In the present study, we used the Epstein criteria [13] . A total of 97.3% (257/264) of lesions were clinically significant in the RP specimens, with a Gleason score ≥7. In other words, only 2.7% of clinically significant lesions were classified as Gleason 6. This suggests that the Epstein criteria might be similar to other definitions that use Gleason 7 as a minimum requirement [21] . Additionally, 36% (94/264) of clinically significant lesions were undetected in the present study, of which 10% (9/94) had a tumour volume ≥0.5 mL. The results indicate that template-guided transperineal saturation prostate biopsy would miss a large proportion of clinically significant lesions with a small tumour volume. If focal therapy was based on the elimination of all clinically significant lesions, this approach would be insufficient for preoperative evaluation. In comparison, Crawford et al. [20] correlated the clinicalpathological results of transperineal mapping biopsy (biopsy cores taken every 5 mm throughout the prostate) with those of the RP specimens. Of the 18 lesions missed by biopsy, only one was clinically significant. The false-negative rate of clinically significant lesions was 4% (1/25). It is clear that transperineal template-mapping biopsy was a more reliable way to detect clinically significant lesions.
Traditionally, focal therapy is conducted based on the anatomical region of the prostate, generally including a quadrant, a lobe or subtotal of the organ [2] . Although the treatment area varies, the therapeutic effect must be guaranteed. Some studies have found the mortality rate for salvage RP after failed focal therapy to be higher than for primary surgery [22] . Fumad o et al. [23] reported that nearly one-third of patients with a unilateral tumour in the biopsy were found to have a clinically significant or index lesion in the contralateral side of the organ. Twelve-core template [23] . Even in the present study, in which the median number of biopsy cores was 24,~20-30% of patients had undetected clinically significant lesions in a different lobe or quadrant compared with the detected ones in the biopsy. This means that focal therapy based on this biopsy approach would miss a large proportion of the clinically significant lesions. On this basis, MRI could be used as an auxiliary method to improve diagnostic ability. Compared with other methods, multiparametric MRI has a higher sensitivity and specificity in the discovery of prostate cancer [24, 25] . For the discovery of high-risk cancer, MRI has obvious advantages [26] . Tsivian et al. [27] pointed out that MRI had a high negative predictive value (84-100%) and specificity (79-85%) in excluding clinically significant cancer [27] . It is generally accepted that MRI examination be served as a way of minimizing the miss rate and therefore enabling focal therapy to be a potentially viable and safe option.
The present study, nevertheless, has some limitations. Firstly, it lacks an MRI comparison because MRI was not included as one of the necessary research steps. As mentioned above, MRI has high sensitivity and specificity for the detection and localization of prostate cancer, especially for the clinically significant lesions. It should serve as a crucial auxiliary method before focal therapy to ensure accuracy and safety. Secondly, the 11-region biopsy method should be optimized. Biopsy of additional regions may help to detect clinically significant lesions with small tumour volume. Lastly, although an experienced pathologist examined all the pathological slices, there is inevitable bias inherent in the lack of a second review of the specimens.
In conclusion, template-guided transperineal saturation prostate biopsy detected approximately two-thirds of clinically significant lesions. Most of the undetected lesions were those with small tumour volume. Approximately 20-30% of patients had undetected clinically significant lesions in a different lobe or quadrant compared with the lesions detected in the biopsy.
